Stock UTHR UNITED THERAPEUTICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus United Therapeutics Corporation

Equities

UTHR

US91307C1027

Real-time Estimate Cboe BZX
Other stock markets
 02:04:13 2024-05-28 pm EDT 		5-day change 1st Jan Change
267.8 USD -1.88% Intraday chart for United Therapeutics Corporation -2.80% +21.65%
May. 16 United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing MT
May. 14 United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing MT

Evolution of the average Target Price on United Therapeutics Corporation

Price target over the last 5 years

History of analyst recommendation changes

c470bef023f8a7d7e167be6ad4a.Wv_s4fHAhWnkZiSOz_4BOL0to3viiJh_fqAhTBqyyPk.boaW2Ji21USWNhzq-MpRc9t9yC-j_6oGNuxQB1jToZ8LyNuWl4_WAdVfHA~e7cc117540172da87e94e89f7008fcc3

Analyst Recommendations on United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing MT
Goldman Sachs Upgrades United Therapeutics to Neutral From Sell, Adjusts PT to $215 From $213 MT
Leerink Partners Starts United Therapeutics with Outperform Rating, $330 Price Target MT
Wedbush Lifts United Therapeutics' PT to $308 From $307 After Higher-Than-Expected Q3 Revenue Driven by Tivaso Franchise; Keeps Outperform Rating MT
Morgan Stanley Adjusts Price Target on United Therapeutics to $318 From $316, Maintains Overweight Rating MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $268 From $256, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
272.9 USD
Average target price
294.2 USD
Spread / Average Target
+7.80%
High Price Target
400 USD
Spread / Highest target
+46.58%
Low Price Target
220 USD
Spread / Lowest Target
-19.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering United Therapeutics Corporation

UBS
Oppenheimer
Goldman Sachs
Leerink Partners
Wedbush
Morgan Stanley
Ladenburg Thalmann
Argus
Credit Suisse
HC Wainwright
JPMorgan Chase
Jefferies & Co.
BTIG
J.P. Morgan Chase

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Consensus United Therapeutics Corporation